Table 4.
Cox multivariate analysis of factors associated with poor survival 18 months after Sorafenib initiation using SarcoMELD composite variable. (A) Training group; (B) Validation group.
| (A) Training Group | ||
| Variable | HR (95% CI) | p-Value |
| SarcoMELD | 1.42 (1.12–1.8) | 0.004 |
| AFP > 25 ng/mL | 1.43 (0.99–2.05) | 0.053 |
| Ascites | 1.35 (0.89–2.03) | 0.157 |
| Macrovascular invasion | 1.3 (0.86–1.98) | 0.213 |
| ECOG–PS | 1.19 (0.95–1.47) | 0.124 |
| CLIP | 1.06 (0.85–1.33) | 0.583 |
| PROSASH-II risk groups | 1.89 (0.89–1.58) | 0.237 |
| (B) Validation Group | ||
| Variable | HR (95% CI) | p -Value |
| SarcoMELD | 1.88 (1.17–3.04) | 0.009 |
| AFP > 25 ng/mL | 1.09 (0.69–1.73) | 0.696 |
| Albumin < 3.8 g/dL | 1.59 (0.86–2.97) | 0.142 |
| Age > 75 years | 0.58 (0.3–1.11) | 0.1 |
| ECOG–PS | 1.5 (1.12–2.01) | 0.006 |
| PROSASH-II risk groups | 1.03 (0.72–1.48) | 0.875 |
Data are expressed as Hazard Ratio and 95% Confidence Interval. Multivariate analysis for OS was made using the Cox proportional hazards model. Significant p-values are highlighted in bold. Abbreviations: AFP, Alpha-fetoprotein; CLIP, Cancer Liver Italian Program; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; MELD, Model for End stage Liver Disease; PROSASH-II, Prediction of Survival in Advanced Sorafenib-treated HCC-II.